Skip to main content
Fig. 1 | BMC Medicine

Fig. 1

From: Estimated nationwide impact of implementing a preemptive pharmacogenetic panel approach to guide drug prescribing in primary care in The Netherlands

Fig. 1

An overview of the genotype predicted phenotypes observed in the IP3 pilot study. Green: extensive/normal metabolizer (CYP2C9, CYP2C19, CYP2D6, DPYD & TPMT) / non-expressor (CYP3A5) / normal transporter activity (SLCO1B1) / normal sensitivity (VKORC1). Orange: intermediate metabolizer (CYP2C9, CYP2C19, CYP2D6, DPYD & TPMT) / heterozygous expressor (CYP3A5). Red: poor metabolizer (CYP2C9, CYP2C19, CYP2D6, DPYD & TPMT) / homozygous expressor (CYP3A5) / poor transporter activity (SLCO1B1) / high sensitivity (VKORC1). Blue: ultra-rapid metabolizer (CYP2C19 & CYP2D6) (see Additional file 1 for an overview of the tested variants)

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us